Meeting
2022 ASCO Quality Care Symposium
Real-world treatment patterns among men with metastatic castration-resistant prostate cancer (mCRPC) in the U.S. Medicare population.
Authors
Stephen J. Freedland
Division of Urology, Department of Surgery, Cedars-Sinai Medical Center and Department of Surgery, Durham Veterans Affairs Health Care System, Durham, NC
Stephen J. Freedland, Matthew Davis, Andrew J. Epstein, Bhakti Arondekar, Jasmina I. Ivanova
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Palliative and Supportive Care,Technology and Innovation in Quality of Care,Quality, Safety, and Implementation Science
Sub Track
Real-World Evidence
Citation
J Clin Oncol 40, 2022 (suppl 28; abstr 406)
DOI
10.1200/JCO.2022.40.28_suppl.406
Abstract #
406
Poster Bd #
F9
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
Real-world treatment patterns among patients with metastatic castration-resistant prostate cancer (mCRPC) in the US.
First Author: Elisabetta Malangone-Monaco
Poster
2017 ASCO Annual Meeting
Efficacy of cabazitaxel (CABA) rechallenge in heavily-treated patients with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Constance Thibault
Poster
2016 Genitourinary Cancers Symposium
Treatment patterns after abiraterone acetate in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Post hoc analysis of COU-AA-302.
First Author: Thomas W. Flaig
Poster
2019 Genitourinary Cancers Symposium
Treatment patterns and outcomes for metastatic castration-resistant prostate cancer (mCRPC) in a real-world setting: A retrospective study of greater than 2500 patients.
First Author: Celestia S. Higano